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Glioblastoma multiforme (GBM) is a heterogeneous malignant brain tumor, the patho-
logical incidence of which induces the accumulation of tumor-infiltrating lymphocytes 
(TILs). As a tumor suppressor gene, LRRC4 is absent in GBM cells. Here, we report that 
the recovery of LRRC4 in GBM cells inhibited the infiltration of tumor-infiltrating regula-
tory T cells (Ti-Treg), promoted the expansion of tumor-infiltrating effector T (Ti-Teff) cells 
and CD4+CCR4+ T cells, and enhanced the chemotaxis of CD4+CCR4+ T cells in the 
GBM immune microenvironment. LRRC4 was not transferred into TILs from GBM cells 
through exosomes but mainly exerted its inhibiting function on Ti-Treg cell expansion 
by directly promoting cytokine secretion. GBM cell-derived exosomes (cytokine-free 
and programmed cell death 1 containing) also contributed to the modulation of LRRC4 
on Ti-Treg, Ti-Teff, and CD4+CCR4+ T cells. In GBM cells, LRRC4 directly bound to 
phosphoinositide-dependent protein kinase 1 (PDPK1), phosphorylated IKKβser181, 
facilitated NF-κB activation, and promoted the secretion of interleukin-6 (IL-6), CCL2, 
and interferon gamma. In addition, HSP90 was required to maintain the interaction 
between LRRC4 and PDPK1. However, the inhibition of Ti-Treg cell expansion and 
promotion of CD4+CCR4+ T cell chemotaxis by LRRC4 could be blocked by anti-IL-6 
antibody or anti-CCL2 antibody, respectively. miR-101 is a suppressor gene in GBM. 
Our previous studies have shown that EZH2, EED, and DNMT3A are direct targets 
of miR-101. Here, we showed that miR-101 reversed the hypermethylation of the 
LRRC4 promoter and induced the re-expression of LRRC4 in GBM cells by directly 
targeting EZH2, EED, and DNMT3A. Our results reveal a novel mechanism underlying 
GBM microenvironment and provide a new therapeutic strategy using re-expression of 
LRRC4 in GBM cells to create a permissive intratumoral environment.
Keywords: ccr4, exosome, programmed cell death 1, regulatory T cells, tumor-infiltrating lymphocytes
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inTrODUcTiOn
Glioblastoma multiforme (GBM) is the most common malig-
nant brain tumor and has a median survival of only 14.6 months 
even after treatment. The 2016 central nervous system (CNS) 
world health organization presents a restructuring of GBM and 
incorporates new entities that are defined by genetic charac-
teristics and histology, including glioblastoma, IDH-mutant; 
glioblastoma, NOS, and glioblastoma, IDH-wild type. In addi-
tion to IDH, other molecular features (i.e., TP53 mutation and 
1p/19q deletion status) are also used to narrowly define entities 
leading to better diagnostic accuracy and more accurate deter-
minations of treatment response and prognosis (1). GBM has 
a heterogeneous composition of true tumor cells and range of 
intermingling non-tumor cells, which also have vital roles in 
controlling the course of the pathology. In fact, the pathological 
incidence of a brain tumor induces the accumulation of tumor-
specific immune cells, which constitute a part of the brain tumor 
mass. These are composed of microglia, the resident immune 
cells of the CNS, and tumor-infiltrating lymphocytes (TILs) 
derived from outside the CNS, as well as even CNS lymphatic 
vessels. TILs include CD4+CD25+FoxP3+ regulatory T (Treg) 
cells, effector T (Teff) cells, and cytotoxic T cells, among others 
(2–5). Each of these TIL subsets exerts different functions and 
secretes specific cytokines that can affect tumor growth. Tumor-
infiltrating effector Th1 cells can exert direct antitumor cytolysis 
and secrete IFNγ, which sustains innate cell activation against 
cancer. Th1 cells also secrete multifunctional cytokines TNFα and 
IL-2. The latter promotes tumor-infiltrating cytotoxic CD8 T cell 
differentiation and the release of perforin, granzyme B, IFNγ, 
and TNFα, which drive tumor regression. Tumor-infiltrating 
effector Th17  cells can support antitumor responses and aug-
ment effector Th and cytotoxic T cell activity. Tumor-infiltrating 
Treg cells expressing FoxP3 produce IL-10 and exert antitumor 
effects by inhibiting tumor-infiltrating effector T  cells in the 
tumor microenvironment (6–10). The GBM microenvironment 
is characterized by high levels of many cytokines. CCL2 secreted 
by GBM cells binds to its receptor on CCR4+ cells to cause them 
to migrate to the tumor microenvironment and surround the 
GBM (Ti-CCR4 cells). CCR4 is expressed on most Treg cells, and 
the binding of CCR4 and CCL2 has been shown to induce Treg 
cell infiltration across the blood–brain barrier into the paren-
chyma (Ti-Treg cells). The CCL2–CCR4 axis is required for Treg 
cell recruitment, and CCR4− deficient Treg cells show defective 
recruitment in brain tumors. CCL2 consistently exerts a dual role 
in the tumor microenvironment. CCR4+ is also expressed on Teff 
(Th2 and Th17, among others) cells, and CCL2 mediates CCR4+ 
Teff cell infiltration of the GBM microenvironment (11–13). 
GBM progression is enabled by immunosuppression driven 
by immunosuppressive cells involving Ti-Treg cells, whereas 
Ti-Teff cells possess tumor-suppressing capabilities (3, 14). 
In addition to Ti-Treg cells, there are multiple, redundant 
immunosuppressive mechanisms associated with GBM, such 
as immunosuppressive cytokines (TGF-β, PGE2, among others), 
immune checkpoints [PDL-1, programmed cell death 1 (PD-1), 
and CTLA-4] and others (3, 15–17). A detailed understanding of 
communication between GBM cells and tumor-specific TILs in 
the GBM microenvironment will help to unveil the key regula-
tory hub of immunosuppressive mechanisms and contribute to 
GBM immunotherapy.
Leucine-rich repeat (LRR) C4 protein (LRRC4, netrin-G1 
ligand-2) is a new partner of PAR6, PAR3, and PKCζ complex 
in axon differentiation. LRRC4 regulates the formation of excita-
tory synapses and promotes neurite outgrowth (18, 19). Previous 
studies have confirmed that LRRC4 is a tumor suppressor gene 
for glioma, is capable of regulating miR-182 and miR-381 and 
constitutes multiphase circuits with transcription factors, gene 
methylation modifications and miRNAs in GBMs, such as the 
LRRC4/NGL-2-miR-185/SP1-DNMT1-LRRC4/NGL-2 loop and 
the LRRC4/NGL-2-AP-2-miR-182-LRRC4/NGL-2 loop. The 
re-introduction of LRRC4 inhibits GBM cell proliferation, migra-
tion, and angiogenesis by downregulating pleiotropic cytokines 
(IGF, EGF, VEGF, SDF-1α, among others) (20–23).
LRRC4 is a member of the LRR superfamily. The LRR domain 
is present in numerous proteins. In humans, 375 LRRC proteins 
have been characterized in innate immunity (24, 25). LRRC4 is 
decreased in WHO grades II and III astrocytomas and is con-
sistently absent in GBM (20). Conversely, the Treg cell fraction 
of TILs in tumors increases with the astrocytomas grade, and 
GBM is characterized by the greatest accumulation of Treg cells. 
Infiltration of Treg cells promotes the development and progres-
sion of GBM (4, 26, 27). These findings suggest a role for LRRC4 
in the GBM microenvironment, and we speculate that the absence 
of LRRC4 may contribute to the infiltration of Treg cells in GBM.
Our previous study has demonstrated a lower expression of 
miR-101 in glioma tissues than in normal brain tissues. Reduced 
miR-101 expression is frequently observed in human glioma tis-
sues, and the reduction of miR-101 expression is not correlated 
with the tumor grade. miR-101 suppresses the expression of EZH2, 
EED, and DNMT3A, inhibits the activity of H3K4 demethylase, 
H3K27 methyltransferase, and DNMT3A methyltransferase, and 
increases the activity of H3K9 and DNMT methyltransferase. 
In addition, miR-101 indirectly suppresses the expression of 
CPEB1, ELFN2, and PRDM16 and affects their methylation 
levels by targeting EZH2, EED and DNMT3A in glioma cells. 
The methylation-mediated LRRC4 inactivation is a frequent 
event in astrocytoma, and we found that the LRRC4 promoter 
was methylated in all glioma cell lines and primary gliomas but 
not in normal brain tissue. The DNA demethylating agent, 5-Aza-
2′-deoxycytidine (5-Aza-dC) reversed LRRC4 hypermethylation 
and induced LRRC4 re-expression in GBM cells (20, 28). Thus, 
we propose that reversing the hypermethylation of the LRRC4 
promoter to restore LRRC4 expression may contribute to the 
treatment of GBM.
Here, we focused on the role of LRRC4 in the GBM immune 
microenvironment by examining tumor tissues, patient 
peripheral blood and primary GBM  cells. Our results showed 
the following. 1. LRRC4 inhibited the infiltration of Ti-Treg 
cells, promoted the expansion of Ti-Teff cells and CD4+CCR4+ 
T  cells, and enhanced the chemotaxis of CD4+CCR4+ T  cells 
in the GBM microenvironment by promoting cytokine secre-
tion and affecting GBM  cell-derived exosomes (cytokine-free 
and PD-1-containing). 2. LRRC4 bound to phosphoinositide 
dependent protein kinase 1 (PDPK1) and HSP90 to promote 
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NF-κB translocation and cytokine production in GBM cells. 3. As 
a potential novel therapeutic agent for GBM, miR-101 modulated 
TIL accumulation by reversing LRRC4 promoter hypermethyla-
tion and induced LRRC4 re-expression in GBM cells.
resUlTs
lrrc4 inhibited the infiltration of Ti-Treg 
cells in gBM by Promoting cytokines 
secretion
As shown in Figure 1A, the expression absence of LRRC4 was 
accompanied by an increase in Foxp3+ Treg cell infiltration in 
GBM (Figure 1A). To test whether the recovery of LRRC4 expres-
sion in GBM cells could inhibit the infiltration of Treg cells in 
GBM tissues, primary cultured GBM  cells, TILs, and periph-
eral blood mononuclear cells (PBMCs) from GBM patients 
were collected (Figure S1A and Table S1 in Supplementary 
Material). We found that tumor-infiltrating CD4+CCR4+ 
T  cells, but not CD4+CCR2+ T  cells, were enriched in GBM 
tissues (Figure S1A in Supplementary Material; Figure  1B), 
suggesting that CD4+CCR4+ T cells had relatively specific infil-
tration in GBM. The fraction of CD4+CCR4+ T  cells in TILs 
was higher than that of PBMCs (Figure  1B). Furthermore, 
the conditioned medium from primary cultured GBM and 
astrocytoma cells transfected with pcDNA3.1 LRRC4 (here-
after referred to as PG-LRRC4 and PA-LRRC4, respectively, 
Figure S1B in Supplementary Material) induced much greater 
CD4+CCR4+ T cell chemotaxis and expansion than that from 
untransfected LRRC4 control cells (Figures  1C,D); however, 
the expansion of tumor-infiltrating CD4+CD25+Foxp3+ 
Treg cells (Ti-Treg) was inhibited (Figure  1E), especially 
the proportion of CD4+CD25+CD127−neuropilin− Ti-iTreg 
cells (Figure  1F, CD127 expression inversely correlates with 
Foxp3 expression, and the combined use of CD4+, CD25+, 
and CD127− can also define the Treg cell population with 
suppressive functions), but drove CD4+ tumor-infliltrating 
effector T  cells (Ti-Teff) expansion (Figure  1G). Ti-Treg and 
Ti-Teff cells are the main subsets of CD4+CCR4+ T cells, and 
they always are recruited into the tumor microenvironment 
via the CCL2/CCR4 axis (12, 29–32). In this study, nine 
primary cultured astrocytoma cells were successfully gained 
in sixteen patient samples (seven cases were WHO grade IV 
GBM cells, one case was WHO grade III, one case was WHO 
grade II). Unfortunately, all of these cells were IDH1 wild type 
with a 1p/19q mutant status and loss of LRRC4 expression 
(Table S1 in Supplementary Material). The effect of LRRC4 
of p53wt and p53mut PG cells on CD4+CCR4+ T cells showed a 
similar tendency. Subsequently, we detected the effect of the 
conditional medium derived from IDH1wt U251 Tet-on-LRRC4 
cells on CD4+CCR4+ T cells, Ti-Treg cells and Ti-Teff cells and 
obtained results that were consistent with those obtained for 
primary cultured GBM cells (Figures S1C–F in Supplementary 
Material). The above data indicated that LRRC4 promoted 
chemotaxis and accumulation of CD4+CCR4+ T  cells, the 
LRRC4 deletion in GBM cells was one cause of the accumula-
tion of Ti-Treg cells (mainly neuropilin− Treg cells) in GBM, 
and re-expression of LRRC4 created a permissive intratumoral 
environment for Ti-Teff cell infiltration by inhibiting Ti-Treg 
cells. These effects were not correlated to the WHO grade or 
molecular typing of the astrocytoma (Figures 1C–G).
To investigate how Ti-Treg cell accumulation was inhibited 
by LRRC4, we measured the levels of 13 cytokines in the con-
ditioned medium of U251 Tet-on-LRRC4 cells by Bioplex array 
analysis and found that re-expression of LRRC4 promoted the 
secretion of 9 cytokines (Figure  1H). In doxycycline (DOX)-
induced U251 Tet-on-LRRC4 cells and PG-LRRC4 GBM cells, 
LRRC4 resulted in increased expression and secretion of inter-
leukin-6 (IL-6) and interferon gamma (IFN-g) (Figure 1I). As 
mentioned previously, CCR4 receptors bind to the chemokine 
CCL2 produced by GBM cells and mediate the chemotaxis of 
T  cells (32). LRRC4 also promotes the expression and secre-
tion of CCL2 in GBM  cells (Figure  1I). To verify whether 
these cytokines were responsible for the modulation of LRRC4 
on T cells, anti-IL-6/CCL2 antibody were used, and we found 
that anti-IL-6 antibody and anti-CCL2 antibody could block 
the inhibition of Ti-Treg cell expansion and the promotion 
of CD4+CCR4+ T  cell chemotaxis by LRRC4, respectively 
(Figure 1J). These results indicated that LRRC4 suppressed the 
accumulation of Ti-Treg cells and increased the expansion of 
Ti-Teff cells by promoting GBM cell cytokine secretion.
lrrc4 inhibited the infiltration of Ti-Treg 
cells via gBM cell-Derived cytokine-Free 
and PD-1-containing exosomes
Exosomes serve as a signaling carrier mediating tumor cell and 
T cell communication (33–39). To test whether LRRC4 affected 
the communication between GBM  cells and CD4+CCR4+ 
T  cells through exosomes, we isolated exosomes from the 
conditioned medium of U251 Tet-on-LRRC4 and PG-LRRC4/
CON cells (Figure  2A) and verified that these exosomes were 
transmitted into TILs (Figure 2B). The exosomes derived from 
LRRC4 overexpression GBM  cells caused significant chemo-
taxis and expansion of CD4+CCR4+ T  cells (Figures  2C,D), 
inhibited the proportion of Ti-Treg cells (Figure 2E), mainly the 
CD4+CD25+CD127−neuropilin− Ti-iTreg cells (Figure 2F), and 
promoted Ti-Teff cell expansion (Figure  2G), consistent with 
the results obtained using the conditioned medium. However, 
these exosomes only slightly reduced the expansion of Ti-Treg 
cells, and we did not detect LRRC4 expression in the exosomes 
or TILs (Figure  2H). Simultaneously, IL-6, IFN-g, and CCL2 
were not transported by exosomes (Figure 2H), suggesting that 
LRRC4 was not transferred into TILs from GBM cells through 
exosomes but mainly exerted its inhibitory function on Ti-Treg 
cell expansion by directly promoting cytokine secretion into the 
conditioned medium of GBM cells.
The kinds of molecules that will be transferred into recipient 
cells through exosomes to exert vital biological functions in 
the presence of LRRC4 in GBM cells are unknown. PD-1 is an 
important target that is applied to melanoma clinical therapy, and 
the expression of PD-1 and its ligand PDL-1 in Treg cells or tumor 
cells protects tumors from immune-mediated rejection and pro-
motes tumor progression (15, 16, 40). We found that PD-1 and 
FigUre 1 | Continued
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PDL-1 were expressed in GBM cells (Figure 2Ia–c) and LRRC4 
decreased the level of PD-1 in GBM cells (Figure 2Ia–c); how-
ever, it did not affect expression in the exosomes (Figure 2Id). 
Interestingly, although LRRC4 did not alter PDL-1 expression 
in GBM cells (Figure 2Ib,c), LRRC4 inhibited PDL-1 that was 
packed into exosomes (Figure 2Id) and reduced the transmission 
of PDL-1 from GBM cells to TILs. Thus, LRRC4 also regulated 
Ti-Treg cells and Ti-Teff cells through cytokine-free and PDL-1-
containing exosomes.
lrrc4 activated nF-κB signaling by 
Binding to PDPK1, and hsP90 is required 
for the interaction of lrrc4 and PDPK1
LRRC4 inhibited Ti-Treg cell accumulation and promoted Ti-Teff 
cell expansion through cytokines in GBM, but the underlying 
mechanism remains unclear. We observed that LRRC4 increased 
the luciferase activity of IL-6, IFN-g, and CCL2 in HEK293 
and GBM cells, respectively (Figure 3A). A number of reports 
FigUre 1 | LRRC4 inhibited the infiltration of Ti-Treg cells in glioblastoma multiforme (GBM) by promoting the secretion of cytokines. (a) Immunohistochemistry 
analysis of Foxp3 and LRRC4 in normal brain (n = 7), grade II astrocytoma (n = 10), grade III astrocytoma (n = 10), and GBM tissues (n = 20). The average IHC 
score was recorded as low expression (score ≤ 8) or high expression (score > 8). (B) Fractions of CD4+CCR4+ T cells and CD4+CCR2+ T cells in tumor-infiltrating 
lymphocytes (TILs) and peripheral blood mononuclear cells (PBMCs) were evaluated by FACS analysis. CD4 population was gated (Figure S1 in Supplementary 
Material). CD4+CCR4+ T cells in TILs were higher than that in PBMC (***P < 0.001). There were no significant differences in the fractions of CD4+CCR2+ T cells 
(P > 0.05). The data summarize the results obtained for the TILs or PBMCs from nine GBM patients; the CD4 population was gated in all flow cytometry analyses  
in this study. (c) The conditioned medium from PG-LRRC4 and PA-LRRC4 cells induced much more CD4+CCR4+ T cell chemotaxis than the conditioned medium 
from PG-CON and PA-CON cells (**P < 0.01, primary GBM and astrocytoma cells transfected by pcDNA3.1-CON/LRRC4 were referred to simply as PG-CON/
LRRC4 and PA-CON/LRRC4). (D–g). The conditioned medium of PG-LRRC4 cells and PA-LRRC4 cells led to enhanced CD4+CCR4+ T cell expansion  
[(D), **P < 0.01], reduced CD4+CD25+Fxop3+ regulatory T (Treg) cell expansion [(e), **P < 0.01], mainly CD4+CD25+CD127−neuropilin1− Ti-iTreg cells  
[(F), **P < 0.01], and an increased percentage of CD4+CD44+CD62L− Teff cells [(g), **P < 0.01 and *P < 0.05] compared with the conditioned medium of  
PG-CON cells and PA-CON cells upon T-cell receptor stimulation (in the presence of anti-CD3/CD28 antibody and IL-2). The data summarize the results of TILs 
from 16 patient samples (9 WHO grade IV GBM patients, 5 WHO grade III grade, 2 WHO grade II grade). (h) The conditioned medium of U251Tet-on-LRRC4 
DOX+/− cells was harvested 24 h later and assayed for 13 different cytokine targets by Bio-Rad BioPlex analysis. (i) The expression and secretion of interleukin-6 
(IL-6), interferon gamma (IFN-g), and CCL2 were increased in U251Tet-on-LRRC4 DOX+ and PG-LRRC4 cells (*P < 0.05, **P < 0.01, and ***P < 0.001). (J) The 
conditioned medium of U251-pcDNA3.1 LRRC4 cells mediating the chemotaxis of CD4+CCR4+ T cells could be blocked by anti-CCL2mAb; the conditioned 
medium of U251-pcDNA3.1 LRRC4 cells mediating the inhibition of Ti-Treg cells could be blocked by anti-IL-6 mAb (**P < 0.01).
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have shown that NF-κB regulates the production of various 
kinds of cytokine in immune cells as well as tumor cells. LRRC4 
elevated the luciferase activity of NF-κB (Figure  3B) and pro-
moted its translocation into the nucleus in DOX-induced U251 
Tet-on-LRRC4 cells (Figures  3C,D). Thus, we questioned how 
LRRC4 induced the nuclear translocation of NF-κB. 3-PDPK1, 
a key regulator of NF-κB activation (15, 16, 40), was a potential 
binding protein of LRRC4 (predicted by scancite 2.0 software). 
PDPK1 promotes IKKβ/NF-κB signaling activation and nuclear 
translocation by directly phosphorylating IKKβ at the Ser181 
residue (41). We first confirmed that LRRC4 and PDPK1 were 
co-localized and interacted in the cytoplasm in HEK293 and 
U251 cells (Figures 3E,F). We further found that LRRC4 could 
upregulate the phosphorylation of IKKβSer181 and pNF-κBp65 
(Figure  3G). Previous literature has reported that the stability 
and signaling of PDPK1 is protected by the molecular chaperone 
HSP90 (heat shock protein 90) (42), and inhibition of HSP90 
results in PDPK1 depletion and thus triggers a cascade of NF-κB 
deactivation. Our study first verified that LRRC4 and HSP90 were 
co-localized and interacted in the cytoplasm (Figures 3H,I), and 
LRRC4 mainly bound to the N-domain of HSP90 and the PH 
domain of PDPK1 (Figure  3I). In addition to HSP90, HSP70 
family members also act as molecular chaperones, but LRRC4 
did not interact with HSPA8 and HSPA5 (Figure 3J). LRRC4 did 
not affect the expression of HSP90 (Figure 3K), but the HSP90 
inhibitor geldanamycin blocked the re-expression of LRRC4 in 
GBM cells (Figure 3L). These results suggested that HSP90 was 
also a molecular chaperone of LRRC4 only in the presence of 
HSP90, and LRRC4 interacted with PDPK1 to activate NF-κB 
and promote its nuclear translocation.
mir-101 reversed lrrc4 
hypermethylation to induce lrrc4  
re-expression in gBM cells
LRRC4 has been verified to be a hypermethylated gene and loss 
expression in glioblastoma (20, 28). miR-101 is a suppressor gene 
for glioma. Re-expression of miRNA-101 could increase LRRC4 
expression (Figures 4A,B) and reverse the LRRC4 hypermethyla-
tion status in GBM cells (Figure 4C), but LRRC4 is not the direct 
target gene of miR-101 (Figure S1H in Supplementary Material). 
Histone methylation modification and DNA methyltransferase 
are critical factors that regulate gene promoter methylation. 
Our previous study found that miR-101 targets DNMT3A, EED, 
FigUre 2 | Continued
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FigUre 2 | Continued  
LRRC4 inhibited the infiltration of Ti-Treg cells by glioblastoma multiforme (GBM) cell-derived cytokine-free and programmed cell death 1 (PD-1)-containing 
exosomes. [(a), a,b] Transmission electron and atomic force microscopy micrographs of exosomes (isolated from the conditioned medium of GBM cells) revealing 
the typical morphology and size. (c) The published exosomal markers CD63, CD81, HSP70, and CD9 were detected. (d) The particle size distribution of EVs was 
measured using the ZetaView® Particle Tracking Analyzer. (B) GBM cell-derived exosomes were stained with PKH67 (green) and incubated with tumor-infiltrating 
lymphocytes (TILs). TILs were visualized using an immunofluorescence microscope (upper panel) and FACS analysis (lower panel). (c) PG-LRRC4 and PA-LRRC4 
cell-derived exosomes induced much more CD4+CCR4+ T cell chemotaxis than PG-CON and PA-CON cell-derived exosomes (**P < 0.01). (D–g) PG-LRRC4 
cell-derived exosomes led to enhanced CD4+CCR4+ T cell expansion [(D), *P < 0.05], reduced CD4+CD25+Fxop3+ regulatory T (Treg) cell expansion, especially  
the expansion of CD4+CD25+CD127−neuropilin1− Ti-iTreg cells [(e,F) *P < 0.05], and an increased percentage of CD4+CD44+CD62L− Teff cells [(g), **P < 0.01] 
compared with PG-CON cell-derived exosomes; TILs isolated from GBM tissues were seeded in 48-well plates, and co-incubated with 20 μg/ml GBM cells-derived 
exosomes under anti-CD3/CD28 conditions. After coculturing 3 days (72 h), TILs were harvested, and CD4+CCR4+ T cells, Treg cells, and Teff cells were analyzed 
by FACS. (c–g). Data summarizing the results obtained for TILs generated from seven GBM patients. (h) LRRC4, interleukin-6 (IL-6), CCL2, and interferon gamma 
(IFN-g) protein levels were absent in U251 tet-on-LRRC4 DOX+/− cell-derived exosomes (upper panel), and no LRRC4 expression was found in PG cells from seven 
cases; matched TILs and normal brain tissues were from two cases (N1 and N2, lower panel). (i) PD-1 (a,c), but not PDL-1 (b,c), levels were increased in U251 
Tet-on-LRRC4 DOX+ and PG-LRRC4 cells compared with U251 Tet-on-LRRC4 DOX− cells and PG-CON cells (*P < 0.05, **P < 0.01, and ***P < 0.001). (d) The 
expression of PDL-1, but not PD-1, was increased in U251 Tet-on-LRRC4 DOX+ cell-derived exosomes compared with U251 Tet-on-LRRC4 DOX− cell-derived 
exosomes (*P < 0.001).
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and EZH2 directly and decreases DNMT3A, EED, and EZH2 
expression (43–46). Hypermethylation was one of the mecha-
nisms of LRRC4 loss in GBM, and therefore we speculated 
that miR-101 promoted LRRC4 expression in a methylation- 
or histone- correlated pattern. Previous studies have confirmed 
the methylation of K4, K9, and K27 on histone H3. H3K4 meth-
ylation typically activates the gene promoter, whereas H3K20 
and H4K27 methylation repress the gene promoter. H3K9 tri-
methylation can repress or activate the gene promoter, and H3K9 
dimethylation represses the gene promoter (47). Here, we found 
that miR-101 decreased H3K27me3 enrichment on the LRRC4 
core promoter [details of the LRRC4 core promoter can be found 
in our previous study (28)] but have no effect on H3K4me2, 
H3K9me3, and H4K20me3 enrichment of the LRRC4 core 
promoter (Figure 4D), which was consistent with the effects of 
EZH2, EED, and DNMT3A inhibitors on histone modifications 
in the core promoter region of LRRC4 (Figure 4E). We also found 
that EZH2, EED, and DNMT3A inhibitors upregulated LRRC4 
expression in GBM cells (Figure 4F). These data indicated that 
miR-101 reversed the hypermethylation of LRRC4 promoter and 
induced the re-expression of LRRC4 in GBM  cells by directly 
targeting EZH2, EED, and DNMT3A to decrease H3K27me3 
enrichment of the LRRC4 core promoter.
In addition, we found that LRRC4 expression was closely 
correlated with the prognosis of astrocytoma patients, with high 
expression of LRRC4 suggesting a good prognosis (Figures 4G,H). 
Moreover, the Cancer Genome Atlas data analysis further 
indicated that classical subtype GBM patients with high LRRC4 
expression had the best prognosis, and neural and proneural 
subtype GBM patients with high LRRC4 expression had a 
longer median survival time than the patients with low LRRC4 
expression (Figure 4I).
mir-101 inhibited Ti-Treg cell infiltration 
in gBM by epigenetically Targeting lrrc4
We wondered whether miR-101 is capable of reversing sup-
pressor gene LRRC4 re-expression in GBM  cells and thus 
whether it could act as a potential drug to improve the immune 
microenvironment of GBM. The conditioned medium from 
miR-101-transfected GBM  cells was obtained and cocultured 
with TILs. We found that the conditioned medium of miR-101 
overexpressed (hereafter referred to as miR-101OV) GBM  cells 
induced more chemotaxis and expansion of CD4+CCR4+ T cells 
than miR-101CON cells (Figures  5A,B). miR-101 inhibited the 
expansion of Ti-Treg cells (Figure 5C), especially the proportion 
of CD4+CD25+CD127−neuropilin− Ti-iTreg cells (Figure 5D), and 
drove Ti-Teff cell expansion (Figure 5E). In addition, we showed 
that miR-101 significantly increased the expression and secretion 
of IL-6, IFN-g, and CCL2 (Figure  5F), and the modulation of 
miR-101 on CD4+CD25+Foxp3+ Ti-Treg cells and CD4+CCR4+ 
T cells could be blocked by anti-IL-6 mAb (Figure 5Ga) and anti-
CCL2 mAb (Figure  5Gb), respectively. Knockdown of LRRC4 
blocked the high expression of cytokines induced by miR-101 
(Figure  5H). In addition, miR-101 only slightly upregulated 
the phosphorylation of IKKβSer181 and pNF-κBp65, suggesting 
that miR-101 regulation of the IKKβ/NF-κB pathway likely con-
sisted of more complex mechanisms (Figure  5I). These results 
demonstrated that miR-101 mediated cytokine secretion to 
modulate T cell accumulation by epigenetically targeting LRRC4 
of GBM cells. miR-101 may be as a potential drug to modulate 
GBM cells and TILs in GBM.
DiscUssiOn
Glioblastoma multiforme is a complex tumor consisting of 
tumor and non-tumor cells, each of which is individually con-
ducive to GBM development and treatment response. Most of 
the non-tumor cells are tumor-infiltrating T cells and microglia, 
among others, that create a supportive stroma microenvironment 
for tumor cell growth and invasion (2–4). Mounting evidence is 
emerging that tumor-infiltrating T cells exert a critical role in the 
GBM microenvironment, but there is little information concern-
ing the interaction of GBM cells and tumor-infiltrating T cells in 
brain tumors. Previous studies have shown that CCR4+ T cells can 
be recruited to the GBM microenvironment (Ti-CCR4+ T cells) 
(12, 32), and our data further indicated that CD4+CCR4+ T cells 
were relatively specifically enriched in GBM and more abundant 
in the tumor microenvironment than those in the peripheral 
blood.
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FigUre 3 | Continued
FigUre 3 | Continued  
LRRC4 facilitated IKKβ/NF-κB pathway activation by binding to phosphoinositide dependent protein kinase 1 (PDPK1), and HSP90 was required for the 
interaction of LRRC4 and PDPK1. (a,B) The Dual-Luciferase Reporter Assay indicated that LRRC4 promoted the transcriptional activity of interleukin-6 (IL-6) 
(***P < 0.001), interferon gamma (IFN-g) (***P < 0.001) and CCL2 [(a), P*** < 0.001], and induced NF-κB activation [(B), ***P < 0.001]. (c) Immunoflorescent 
staining for NF-κB-p65 revealed the nucleus translocation in U251 Tet-on-LRRC4 DOX+ cells compared with U251 Tet-on-LRRC4 DOX− cells. (D) The expression 
of NF-κB-p65 was mainly detected in the nucleus in U251 Tet-on-LRRC4 DOX+ cells. (e) Representative confocal and immunofluorescence images showing the 
co-localization of LRRC4 (green) and PDPK1 (red) in the cytoplasm in HEK293 and U251-pcDNA 3.1 LRRC4 cells. (F) Co-IP analysis showing the interaction 
between LRRC4 and PDPK1 in HEK293 and U251-pcDNA 3.1 LRRC4 cells. (g) Western blot analysis showing that the expression of pIKKβSer181 and pNF-κB 
p65 was increased in U251 Tet-on-LRRC4 DOX+ cells and PG-LRRC4 cells. (h) Representative confocal and immunofluorescence images showing the 
co-localization of LRRC4 (green) and HSP90 (red) in the cytoplasm in HEK293 and U251-pcDNA 3.1 LRRC4 cells. (i) Co-IP analysis showing the interaction 
between LRRC4 and HSP90 in U251-pcDNA 3.1 LRRC4 cells (up); GST pull-down assay showing that LRRC4 mainly bound to the N-domain of HSP90; LRRC4 
mainly bound to the PH domain of PDPK1 (down). (J) Co-IP analysis showing no interaction between LRRC4 and HSPA5 and HSPA8 in U251-pcDNA 3.1 
LRRC4 cells. (K) Western blot analysis of the levels of HSP90 showing no alteration in U251 Tet-on-LRRC4 DOX cells and PG-CON/LRRC4 cells. (l) The 
expression of LRRC4 was decreased when HSP90 activity was inhibited. The U251-pcDNA 3.1 LRRC4 cells were treated with selected concentrations and 
durations of the HSP90 inhibitor geldanamycin.
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LRRC4 is a tumor suppressor gene for glioma (20). Our 
research showed that re-expression of the suppressor gene LRRC4 
in GBM cells mediated the interaction between GBM cells and 
tumor-infiltrating T cells. Re-expression of LRRC4 in GBM cells 
enhanced chemotaxis of CD4+CCR4+ T cells by promoting CCL2 
production, and reports have confirmed that CCL2 contributes to 
CD4+CCR4+ T cell accumulation in GBM. We also showed that 
Treg cell infiltration in the tumor microenvironment increased 
with the astrocytomas grade and that almost all Ti-Treg cells 
expressed the CCR4 receptor, whereas LRRC4 expression showed 
a negative correction with Ti-Treg cells in GBM. Interestingly, 
re-expression of LRRC4 in GBM cells stimulated the accumula-
tion of CD4+CCR4+ T cells but simultaneously inhibited CCR4+ 
Ti-Treg cell expansion and facilitated Ti-Teff cell expansion. This 
finding implied that LRRC4 may play a dual role to construct 
a positive immune microenvironment through Ti-Treg inhibi-
tion and Teff cell promotion. Simultaneously, this phenomenon 
probably explained why the expression of LRRC4 in GBM cells 
inhibited the expansion of CCR4+ Treg cells, but the proportion of 
CD4+CCR4+ T cells continued to increase. Our data further dem-
onstrated that LRRC4 significantly facilitated IL-6 production by 
GBM cells and mediated the interaction between GBM cells and 
Ti-Treg cells via IL-6. Recent studies have shown that IL-6 induces 
the differentiation of naïve T cells into Teff cells but not Treg cells, 
polarizes Treg cells to adopt a Teff cell phenotype and blocks the 
suppressor activity of Treg cells (13, 48, 49). These functions of 
IL-6 probably explain the ability of LRRC4 in GBM cells to inhibit 
Ti-Treg cells. Collectively, our results showed that re-expression 
of LRRC4 in GBM cells modulated the GBM microenvironment 
through multiple cytokines.
In addition to cytokines, exosomes also serve as signaling tools 
mediating tumor cell and T cell communication. For example, in 
nasopharyngeal carcinoma, colorectal cancer, and lung cancer, 
tumor cell-derived exosomes modulate Treg cell expansion 
(50–52). Exosomes secreted by cancer cells involving glioma 
cells have been shown to express immunosuppressive molecules 
such as PDL-1 or PD-1 (15, 16, 40). PD-1 is a checkpoint receptor 
that, upon engagement by PDL-1, dampens Teff cell functions 
by inhibiting T-cell receptor signaling. The PDL-1–PD1 axis 
induces apoptosis or exhaustion of activated immune cells, 
converting naive T  cells, and TH cells into Treg cells, and the 
constitutive expression of PDL-1 and PD-1 on Treg cells regulates 
the formation of stable and productive immunological contacts, 
providing a novel mechanism of suppression that is utilized by 
Treg cells. Furthermore, PD-1 is also expressed in several types 
of cancer (including glioma, breast cancer, lung cancer, among 
others) and promotes cancer progression. Thus, the PDL-1–PD1 
axis protects tumor from immune cell-mediated rejection, and 
exosomes (containing PD-1 and/or PDL-1) immune suppres-
sion is associated in some situations with a tumor-suppressive 
microenvironment (15, 16, 40). In this study, we also verified the 
critical role of exosomes in the modulation of the GBM microen-
vironment. Exosomes derived from LRRC4-recovered GBM cells 
caused a significant chemotaxis and expansion of CD4+CCR4+ 
T cells facilitated Ti-Teff cell expansion and inhibited the propor-
tion of Ti-Treg cells. In contrast to previous reports, we found 
that PDL-1 and PD-1 were expressed together in GBM cells, and 
GBM  cell-derived exosomes contained both PDL-1 and PD-1, 
with much lower levels of PD-1 than PDL-1. Interestingly, the 
recovery of LRRC4 in GBM cells only inhibited PDL-1 packing 
into exosomes and reduced the transmission of the ligand PDL-1 
in GBM  cells. PDL-1/PD-1 pathway from ligand and receptor 
aspects attenuated by LRRC4 contributed to the modulation of 
LRRC4-recovery GBM cells-derived exosomes on immune cells. 
We also found that LRRC4 in GBM cells was not transferred into 
TILs through exosomes, and cytokines (IL-1, IFN-g, and CCL2) 
were simply directly secreted into the conditioned medium.
In the future, multi omics analysis will be implemented in 
exosomes, and we will further focus on the contribution of the 
PD-1/PDL-1 pathway using molecular imaging and PD-1/
PDL-1 knockdown/overexpression in exosomes to reveal the 
mechanisms of LRRC4 in GBM microenvironment immune cells 
modulation through exosomes.
As described earlier, re-expression of LRRC4 in GBM  cells 
modulated CD4+CCR4+ T cells through multiple cytokines, but 
the underlying mechanism remains unclear. It is well known that 
NF-κB plays a critical role in inflammation and is a transcription 
factor for a number of immune-related genes (IL-6, CCL2, among 
others) involved in immune responses; thus, it plays a dual role in 
promoting and inhibiting cancer (53). It is also clear that PDPK1 
is a kinase that phosphorylates several members of the protein 
kinase A, G, and C family, and PDPK1 directly phosphorylate 
IKKβ to activate NF-κB signaling (41). Our studies have revealed 
that LRRC4 is a novel regulator of PDPK1/NF-κB signaling. 
FigUre 4 | miR-101 reversed the hypermethylation of LRRC4 and induced LRRC4 re-expression in glioblastoma multiforme (GBM) cells by targeting EZH2, EED, 
and DNMT3A. (a) The miR-101 level was increased after GBM cells were transfected with miR-101/NC (*P < 0.001). (B) miR-101 promoted LRRC4 mRNA 
expression (*P < 0.05). (c) miR-101 reversed the hypermethylation status of LRRC4 by MSP in GBM cells; U, unmethylated primer; M, methylated primer.  
(D) H3K27me3 occupancy of the LRRC4 core promoter was inhibited by miR-101. A ChIP assay was used to detect the H3K4me2, H3K27me3, H3K9me3, and 
H4K20me3 occupancy of the LRRC4 core promoter (*P < 0.05). (e) H3K27me3 occupancy of the LRRC4 core promoter was inhibited by EZH2 siRNA, EED siRNA, 
and DNMT3A siRNA. A ChIP assay was performed to detect the H3K4me2, H3K27me3, H3K9me3, and H4K20me3 occupancy of the LRRC4 core promoter. 
GBM cells were transfected with EZH2 siRNA, EED siRNA, and DNMT3A siRNA (*P < 0.05). (F) LRRC4 expression was increased after GBM cells were transfected 
with EZH2 siRNA, EED siRNA, DNMT3A siRNA, or a siRNA NC (*P < 0.05). (g) LRRC4 expression in GBMs and normal brain tissues from the Cancer Genome 
Atlas (TCGA). (h) Kaplan–Meier curve analysis indicated that the high LRRC4 expression was correlated with a better survival prognosis in astrocytoma patients 
(n = 50). (i) Kaplan–Meier curve analysis in four subtypes of TCGA GBM patients (classical, neural, proneural, and mesenchymal) stratified by LRRC4 expression. 
Classical subtype GBM patients with high LRRC4 expression had a better overall survival, and the median OS was higher in high LRRC4 expression than in low 
LRRC4 expression patients with neural and proneural GBM.
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FigUre 5 | Continued
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LRRC4 directly binds to PDPK1 in the presence of the molecular 
chaperone HSP90 and facilitates IKKβ ser181 and NF-κBp65 phos-
phorylation, promotes NF-κB nuclear translocation and activates 
NF-κB signaling to facilitate IL-6, CCL2, and IFN-g transcript 
and secretion. Overall, we show that LRRC4 exerts its inhibitory 
function on CD4+CCR4+ T cells in the GBM microenvironment 
via the PDPK1/IKKβ/NF-κB/cytokine pathway, and our findings 
provide new insights into PDPK1/NF-κB signaling.
FigUre 5 | Continued  
miR-101 inhibited Ti-Treg cell expansion by restoring LRRC4 expression. (a) The conditioned medium from miR-101 overexpression glioblastoma multiforme (GBM) 
cells induced much more CD4+CCR4+ T cell chemotaxis than the conditioned medium from control cells (**P < 0.01). (B–e) The conditioned medium from miR-101 
overexpression GBM cells led to enhanced CD4+CCR4+ T cell expansion [(B), *P < 0.05], reduced CD4+CD25+Fxop3+ regulatory T (Treg) cell expansion  
[(c), **P < 0.01], mainly neuropilin1− Ti-iTreg cells [(D), *P < 0.05], and an increased percentage of CD44+CD62L− Teff cells [(e), **P < 0.01] compared with the 
control cell conditioned medium upon T-cell receptor stimulation (in the presence of anti-CD3/CD28 antibody and IL-2); the data in panels (B–e) summarize the 
results obtained for TILs from seven GBM patients. (F) miR-101 facilitated the expression and secretion of interleukin-6 (IL-6), interferon gamma (IFN-g), and CCL2 
in GBM cells (*P < 0.05, **P < 0.01, and ***P < 0.001). [(g), upper] The conditioned medium of miR-101 overexpression GBM cells mediating the inhibition of 
Ti-Treg cells could be blocked by anti-IL-6 mAb (**P < 0.01). (lower) The conditioned medium of miR-101 overexpression GBM cells mediating the chemotaxis of 
CD4+CCR4+ T cells could be blocked by anti-CCL2 mAb (**P < 0.01). (h) LRRC4 siRNA 1074 and siRNA 1929 blocked the high level of expression and secretion 
of IL-6, IFN-g, and CCL2 induced by miR-101 (*P < 0.05, **P < 0.01, and ***P < 0.001). (i) The expression of pIKKβ Ser181 and pNF-κB p65 was increased in 
GBM cells transfected with miR-101.
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miR-101 is a tumor suppressor in some cancers, such as astro-
cytoma, hematomas, and breast cancer (54). According to many 
literature reports, overexpression of miR-101 targets many genes 
(such as STMN1, RAB5A, ATG4D, EZH2, EED, SOX9, COX-2, 
ATP5A1, ATP5B, and KLF6) and regulates their expression in 
GBM cells. In our previous study, we also verified that overex-
pression of miR-101 directly targeted genes involving DNMT3A, 
ELFN2, PRDM16, and CPEB1 and downregulated their expres-
sion. Furthermore, miR-101 indirectly targeted LMO3, CPEB1, 
ELFN2, and PRDM16 and regulated the expression of these 
genes by reversing their methylation status. Here, we found that 
LRRC4 was not the direct target gene of miR-101, but miR-101 
was capable of reversing the LRRC4 hypermethylation status and 
expression in GBM cells. Hereby, we propose that miR-101 could 
be as a small molecule that participates in the recovery of LRRC4 
expression in GBM cells and further affects CD4+CCR4+ T cells 
in the GBM microenvironment. Fortunately, we verified that 
miR-101 inhibited Ti-Treg cell expansion facilitated Ti-Teff cell 
expansion and CD4+CCR4+ T cell chemotaxis by epigenetically 
targeting LRRC4 in GBM cells. LRRC4 knockdown blocked the 
secretion of cytokines mediated by miR-101. Our previous study 
has shown that DNMT3A, EED, and EZH2 are direct targets of 
miR-101 in GBM  cells, and histone methylation modification 
and DNA methyltransferase are critical factors that regulate gene 
promoter methylation (43–46, 54). H3K27 could repress the gene 
promoter to inhibit gene expression. In our study, we showed 
that miR-101 reversed LRRC4 hypermethylation by directly 
targeting EZH2, EED, and DNMT3A to decrease H3K27me3 
enrichment of the LRRC4 core promoter. High expression of 
LRRC4 suggested a good prognosis in classical GBM patients, 
and a similar tendency was observed in neural and proneural 
GBM patients. Accordingly, as a small molecule that participates 
in the re-expression of LRRC4, miR-101 may serve as a poten-
tial therapeutic molecule for GBM, mainly for classical GBM 
treatment. In conclusion, this study demonstrated that LRRC4 
re-expression in GBM cells mediated the accumulation of GBM-
infiltrating CD4+CCR4+ T cells through cytokines and exosomes. 
In GBM cells, LRRC4 directly bound to PDPK1 and HSP90 and 
activated PDPK1/IKKβ/NF-κB signaling to promote cytokine 
secretion. miR-101 could be a small molecule capable of reversing 
LRRC4 expression through epigenetic mechanisms to mediate 
the interaction of GBM cells and GBM-infiltrating CD4+CCR4+ 
T cells (Figure 6). Our results identify a novel mechanism in the 
GBM microenvironment and suggest a new treatment method 
using LRRC4 re-expression in GBM cells to create a permissive 
intratumoral environment.
MaTerials anD MeThODs
collection of human Biological samples 
and Primary Tumor cell culture
Human clinical sample and data were collected from the 
Department of Neurosurgery, Central South University. All human 
experiments were performed in accordance with the Declaration 
of Helsinki and approved by the Joint Ethics Committee of the 
Central South University Health Authority. All subjects provided 
informed written consent. Primary tumor samples were minced 
with a GentleMACS Dissociator (Miltenyi Biotec). Cells were 
cultured in DMEM/F12 containing 10% FBS. Primary tumor 
cells were tested by GFAP, nestin, and CD133 staining and sub-
cutaneous implantation in nude mice.
immunohistochemical staining
The immunohistochemical experiment was performed using 
the Ultra Sensitive SP Kit (Maixin Biotechnology Company). 
Two independent pathologists who were blinded to the clinical 
pathological information performed the scoring.
Flow cytometry
Peripheral blood mononuclear cells and TILs were thawed in PBS 
and washed in fluorescence-activated cell sorting staining buffer. 
Single cell suspensions were assessed using a BD Biosciences 
LSRII flow cytometer and fluorochrome-conjugated antibodies 
against CD4, CD25, CD127, Foxp3, CD304 (neuropilin1), CCR4, 
CCR2, CD44, and CD62L. The results were analyzed using FlowJo 
software.
luciferase reporter assay
This procedure was carried out as previously described (55). 
Firefly and Renilla reniformis luciferase activities were measured 
24  h after transfection using the dual-luciferase reporter assay 
system (Promega, Madison, WI, USA).
Migration assay
Tumor-infiltrating lymphocytes were seeded in the upper part of 
a Boyden chamber; the lower part contained tumor cell-derived 
exosomes (56, 57). The percentage of migrating cells was evaluated 
FigUre 6 | Schematic diagram. (a) LRRC4 mediated the interaction between glioblastoma multiforme (GBM) cells and CD4+CCR4+ T cells by cytokines and 
exosomes: LRRC4 re-expression in GBM cells recruits CD4+CCR4+ T cells involving regulatory T (Treg) cells and Teff cells into the GBM microenvironment through 
CCL2 and exosomes, while LRRC4 re-expression in GBM cells can inhibit CD4+CD25+Foxp3+ tumor-infiltrating Treg cells (CD4+CD25+Foxp3 Ti-Treg) expansion and 
facilitate tumor-infiltrating Teff (Ti-Teff) cell expansion by interleukin-6 (IL-6), interferon gamma (IFN-g), and exosomes (cytokine-free and programmed cell death 
1-containing) secretion. The inhibition of Ti-Treg cells is also responsible for the expansion of Ti-Teff cells. (B) LRRC4 interacted with phosphoinositide dependent 
protein kinase 1 (PDPK1) and HSP90 to promote NF-κB nuclear translocation and cytokine secretion in GBM cells: as a novel regulator of PDPK1/NF-κB signaling, 
LRRC4 bound to PDPK1 in the presence of the molecular chaperone HSP90, increased IKKβser181 phosphorylation and NF-κB nuclear translocation, and activated 
NF-κB signaling to facilitate the expression and secretion of IL-6, CCL2, and IFN-g. (c) miR-101 reversed LRRC4 hypermethylation to induce LRRC4 re-expression: 
miR-101 reversed the hypermethylation of LRRC4 by directly targeting EZH2, EED, and DNMT3A to decrease H3K27me3 enrichment of the LRRC4 core promoter.
13
Li et al. LRRC4-Guided Interaction between GBM Cells and CCR4+ T Cells
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1748
by flow cytometry (BD Biosciences LSRII flow cytometer), and 
the results were analyzed using FlowJo software.
co-immunoprecipitation
For the LRRC4-PDPK1, LRRC4-HSP90, and PDPK1-HSP90 
interactions, 107 cells were prepared and lysed with GLB+ buffer. 
Antibodies were incubated with the cell lysate, and then the 
solution was incubated with Protein G beads (Thermo Scientific, 
20399). After the beads were boiled, the lysates were subjected to 
Western blotting.
gsT Pull-down assay
Bacterial lysates containing GST-PDPK1 domains or GST-HSP90 
domains were incubated with glutathione-Sepharose 4B beads. 
The beads were incubated with cell lysates containing LRRC4, 
allowing the LRRC4-PDPK1 or LRRC4-HSP90 interaction. 
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The interacted proteins were eluted and subjected to electro- 
phoresis.
chiP assay
This procedure was carried out as previously described (54). 
A total of 2 × 107 cells were used for the ChIP assay. Antibodies 
specific to trimethylated H3K27, dimethylated H3K4, trime-
thyl-H4K20 and trimethylated H3K9 were used (Millipore). 
Immunoprecipitated DNA from ChIP analyses with anti-
H3K27me3, anti-H4K20me3, anti-H3K9me3, and anti-H3K4me2 
antibodies was subjected to a RT-qPCR experiment.
statistical analysis
All experiments were performed three times, and the data were 
analyzed with GraphPad Prism 5. Differences between the variables 
of the groups were tested using the Student’s t-test and Kaplan–
Meier curves analysis, among others. A P-value  <  0.05 was 
considered statistically significant.
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by the “Joint Ethics Committee of the Central South University 
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